Science-backed by wellness with IMMBO
This section presents the scientific and clinical research related to IMMBO, providing an evidence-based overview of its therapeutic potential in managing allergic and respiratory conditions while supporting immune balance. Developed as a proprietary Ayurvedic formulation, IMMBO has been studied through clinical observations, case documentation, and research initiatives to better understand its role in addressing hypersensitivity responses, particularly in conditions such as allergic rhinitis.
The research compiled here explores the formulation’s potential mechanisms of action, including its influence on immune regulation, inflammatory responses, and cellular pathways associated with allergic reactions. Environmental triggers such as dust, pollen, pollution, and seasonal changes often lead to exaggerated immune responses that contribute to respiratory allergies. The studies presented in this section examine how IMMBO may help modulate these responses, reduce inflammatory activity, and support the body’s natural defense mechanisms.
By documenting clinical outcomes and scientific observations, this research aims to provide healthcare professionals, researchers, and practitioners with transparent and credible insights into IMMBO’s therapeutic profile. It also reflects a broader effort to evaluate traditional Ayurvedic formulations within modern scientific frameworks, helping bridge classical knowledge with contemporary research methodologies.
This page serves as a growing repository of studies, findings, and research insights related to IMMBO. As new clinical data and research observations emerge, they will be added here to further strengthen the evidence base and support informed clinical use in the management of allergic, respiratory, and immune health.
Fast Acting
- 90% symptoms improved within first 15 minutes.
- No adverse drug reaction reported.
| S. No. | Symptoms | Subjects | Observation time (in minutes) | ||||
|---|---|---|---|---|---|---|---|
| 2 | 5 | 10 | 15 | 30 | |||
| 1 | Sneezing | 132 | 38 | 53 | 18 | 20 | - |
| 2 | Itchy nose | 110 | 12 | 59 | 27 | 9 | - |
| 3 | Itchy Palate | 84 | 2 | 26 | 41 | 12 | 3 |
| 4 | Rhinorrhea | 125 | 4 | 51 | 28 | 37 | 3 |
| 5 | Nasal Obstruction | 94 | 1 | 13 | 20 | 24 | 28 |
| 6 | Conjunctival Hyperemia | 78 | 0 | 8 | 33 | 22 | 11 |
| 7 | Rhinorrhea | 89 | 1 | 15 | 42 | 23 | 6 |
Single dose effect (n=154) (Age group: 10-65 years)
Effective and Safe
Immbo is more effective than Levocetirizine and non sedative
- Four times more effective than Levocetirizine
- Four times fewer side effects as compared to Levocetirizine
(n=180)
Gr A – Immbo 3 gm/day*,
Gr B – Levocetirizine 10 mg/day,
Gr C – Immbo 3 gm*+Levocetirizine 10mg/day
Maximum improvement was seen in the group which was given Immbo, followed by the group given Immbo and Levocetirizine and then the group which was given Levocetirizine. Similarly, side effects were least reported in the group taking Immbo.
Effect With Objectivity
Significantly reduces IgE levels depicting its immuno-modulatory properties
IgE, or Immunoglobulin E, is a type of antibody involved in allergic reactions and the body’s response to parasitic infections. A high level of IgE (immunoglobulin E) in the blood generally indicates an allergic response or condition.
Effect with Objectivity
IMMBO clears nasal congestion in no time
Significantly reduces Total Nasal Symptom Score (TNSS) levels
The Total Nasal Symptom Score (TNSS) is the sum of scores for each of nasal congestion, sneezing, nasal itching, and rhinorrhea, using a four point scale (0-3), where O indicates no symptoms, a score of 1 for mild symptoms that are easily tolerated, 2 for moderate symptoms which are bothersome but tolerable and 3 for severe symptoms that are hard to tolerate and interfere with daily activity. TNSS is calculated by adding the score for each of the symptoms to a total out of 12.
Science Behind the Effect
Shows immunomodulatory properties in immunosuppressed experimental models
Wistar albino rats (6–8 weeks old); n=24
Immunosuppression induced using Cyclophosphamide (100 mg/kg); challenged with SRBC
Levamisole is a known anti inflammatory, used as reference drug
IMMBO shows hypersensitivity response comparable to that of Levamisole.
The group which given not given any treatment was used as the negative control group (SRBC control).
The hypersensitivity response in Immbo group was comparable to that of Levamisole group.
Mean increase in paw thickness (in mm)
Pro-inflammatory Response
Effect similar to reference drug, Levamisole
Shows Neutrophil adhesion
A neutrophil adhesion assay is a test that measures how well neutrophils stick to a surface which plays an essential prevent infections by blocking, disabling, digesting, or warding role in the formation of an inflammatory exudate.
Neutrophils help off invading particles and microorganisms.
| Group 1 | Healthy Control |
|---|---|
| Group 2 | Cyclophosphamide (Immunosuppressant) |
| Group 3 | Cyclo + SRBC (Antigen stimulation) |
| Group 4 | Cyclo + SRBC + Levamisole |
| Group 5 | Cyclo + SRBC + IMMBO 200 mg/kg body wt. |
| Group 6 | Cyclo + SRBC + IMMBO 400 mg/kg body wt. |
| Group 7 | Cyclo + SRBC + IMMBO 800 mg/kg body wt. |
Higher doses of IMMBO significantly increases neutrophil adhesion.
Mid dose IMMBO showed neutrophil adhesion comparable to Levamisole.
Immunostimulant
Immbo helps in recognizing and fighting antigens
Significantly increases levels of IgM, IgG and IgA levels
Immunoglobulins, also known as antibodies, are glycoprotein molecules produced by plasma cells to help the body fight off infections and other foreign substances.
They play a crucial role in the humoral immune response by recognizing and neutralizing antigens.
IMMBO significantly increases levels of IgM, IgG and IgA with increasing doses.
Cytokine Modulator
- Normalizes cytokine expression in immunosuppressed animals.
- Cyclophosphamide is an immunosuppressant that can either reduce or elevate cytokine biomarkers. IMMBO helps restore these levels toward normal.
- Cytokines are small signaling proteins that act as messengers, regulating immune responses and controlling inflammation.
- IMMBO helps normalize the levels of various cytokines when administered to immunosuppressed animals.
Cytoregulator
Immbo helps in regulation of cell cycle
Normalizes cell regulatory markers suggesting its role in cell regulation.
Cell regulation is the process that controls the series of events by which a cell goes throughout the cell cycle. Disruption of normal regulation of the cell cycle can lead to diseases.
IMMBO normalizes cell regulatory markers in immunosuppressed animals.
Anti Histaminic
Anti histaminic property makes Immbo anti allergic.
Exhibits potential to inhibit histamine release from mast cells suggesting its role as anti-allergic.
Potential of IMMBO for inhibition of histamine release from mast (P815) cells; Lower IC50 value means higher efficacy.
Cromolyn sodium is a herbal extract that has mast cell stabilizer property and used in treating various allergic conditions and possesses anti-histaminic properties
Histamine is released by immune cells like mast cells and basophils in response to allergens, causing inflammation and other allergy symptoms like sneezing, itching, and runny nose. Anti-allergics block i=histamine release.
Natural Killer Cell Properties
Exhibits NK cell activity suggesting its role as an immuno-modulator.
| Sample | Concentration (µg/ml) | % NK cell activity |
|---|---|---|
| IMMBO | 200 | 83.69 |
| 100 | 78.87 | |
| 50 | 56.58 | |
| 25 | 34.14 | |
| 12.5 | 16.95 | |
| Lipopolysaccharide | 0.5 | 77.16 |
| 1 | 81.46 | |
| Control (RPMI-1640) | -- | 20.25 |
Natural killer (NK) cells are a type of white blood cell that serve as a first-line defense against viruses and tumor cells.
They help the body fight infection and cancer.